Bioline RX Ltd Sponsored ADR (BLRX) has released an update.
BioLineRx Ltd. has announced substantial commercial achievements for APHEXDA, including securing payer coverage for roughly 95% of U.S. lives and initiating a Phase 2b trial for pancreatic cancer treatment. The company has also reported a successful launch of APHEXDA in the U.S. and positive progress in collaborations, with financial results showing $4.8 million in revenue for the year 2023.
For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.